What if we let RA patients choose ttmt? BACH RCT choice between Filgo / scTNFi vs. standard randomisation 55% JAKi vs 45% TNFi Higher ttmt satisfaction 46 vs 33 p=0.012 Less ttmt switches 6 vs 15 p=0.026 Less AE reported Better drug survival Shared decision making is key! https://t.co/1YS0y6YUEH

• https://x.com/AurelieRheumo/status/2062443937332154751/photo/1
• https://x.com/AurelieRheumo/status/2062443937332154751/photo/1
• https://x.com/AurelieRheumo/status/2062443937332154751/photo/1

Does ASA protect against JAKi-associated VTE in #RA? Swedish data (n=26,116): No. JAKi VTE risk remained elevated vs TNFi regardless of concomitant ASA or DOAC use. NSAIDs showed a non-significant trend toward protection. @RheumNow #EULAR2026 POS0068

📈 Do SIJ lesions progress in #axSpA? DESIR cohort (n=649, 10yrs): Yes, slowly, but bDMARDs reduce erosion progression #OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4

• https://x.com/Nellziade/status/2062240461708812751/photo/1

Cancer risk with JAK inhibitors remains a major focus at #EULAR2026. In #OP086, analysis from 14 international RA registries and >60000 treatment courses found no statistically significant increase in overall or subtype-specific malignancy risk with JAKi versus TNFi. @RheumNow https://t.co/JeOmTufYwo

• https://x.com/DrMiniDey/status/2062203405049933870/photo/1

#OP085 from Sweden adds more real-world data to the JAKi safety discussion at #EULAR2026. In >26000 RA treatment initiations, JAKis were associated with higher VTE risk vs TNFi (HR 1.89), with similar findings persisting in 2021-2024 data. @RheumNow https://t.co/YRjPNZ8mmo

• https://x.com/DrMiniDey/status/2062199881616544086/photo/1

🎯 Does Tofacitinib work in axial #PsA? #POS0049: 1st RCT (PASTOR, n=26): improved MRI & clinical outcomes vs placebo @ wk12 #EULAR2026 @rheumnow

What’s in the pipeline for #psoriatic_arthritis treatment? A special focus on Tyk2 inhibitors WIN session at #EULAR2026 @RheumNow https://t.co/dDJtmdx9xU

• https://x.com/Nellziade/status/2062174411789050339/photo/1

What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects of Axial involvement https://t.co/v9cfn1y4fH

• https://x.com/AurelieRheumo/status/2062175008340730028/photo/1